Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

Administration of a single 50 mg or 200 mg dose of tigecycline will not cause a change in QT/QTc intervals.

Key facts

Study ID

NCT01287793

Run by

Pfizer

People needed

48

Starts

2011-01-01

Expected to finish

2011-05-01

Last updated by the study team

2011-05-24

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy
• Body mass index 17.5 - 30.5 kg
• Total body weight greater than 50 kg

You may not qualify if…

• Recent history of diarrhea
• Use of oral antibiotics in the last 2 weeks
• History of risk factors for QT prolongation pregnant females
• Nursing females

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.